Primary Brain Tumor Radiotherapy with Concurrent and Adjuvant Temozolomide: Its Outcomes in Terms of Survival and Toxicity

Background: To assess the outcome of primary brain tumor radiotherapy with concurrent and adjuvant temozolomide. Material and Methods: A total of 42 patients who were histologically proven primary malignant brain tumor with nonmetastatic, ECOG (Eastern Cooperative Oncology Group) performance status 0, 1, and 2 were enrolled in this study. Results: All patients underwent craniotomy with gross total excision (GTE) 66.7% and partial excision 33.3%. Post craniotomy, patients were diagnosed as grade II 28.6%, grade III 23.8%, grade IV 42.9%, and glio-sarcoma 4.8%. Post radiotherapy with concurrent and adjuvant temozolomide, two years of overall survival were 83.3%, 60%, and 25% in grade II, grade III, and high-grade glioma, respectively. Conclusion: This study concluded that radiotherapy is an integral part of treatment in primary malignant brain tumor. Temozolomide (TMZ) in concurrent and adjuvant setting had additional survival benefit.